Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The continuous dissemination of coronavirus disease of 2019 (COVID-19) literature can inform decision-makers and the public. Since the widespread use of COVID-19 vaccines, more systematic reviews have summarized the effectiveness and reported adverse events associated with vaccination. Previous systematic and scoping reviews on COVID-19 summarized various aspects surrounding COVID-19, however, a scoping review is needed to summarize the characteristics of COVID-19 vaccines and associated adverse events reported in systematic reviews and meta-analyses to provide comprehensive evidence for informed medical decision-making. We will conduct a scoping review concerning COVID-19 vaccines and adverse events from vaccines. We will search from December 2019 to present in Epistemonikos, Campbell Library, CINAHL (Ovid), MEDLINE (Ovid), Scopus, CENTRAL (Ovid), Web of Science, WHO COVID-19 database, Joanna Briggs Institute of Excellence, and COVID-19 Evidence Reviews resource. We will include systematic reviews, meta-analyses, or both of randomized controlled trials and observational studies and exclude individual randomized controlled trials and observational studies. Abstracts and full-texts will be screened prior to selection. Investigators will independently use a calibrated quantitative and qualitative data extraction sheet and rate the quality of articles with AMSTAR, resolving disagreements to aim for good agreement (≥80%). An updated scoping review of the characteristics and safety of COVID-19 vaccines would highlight the accuracy of the evidence to inform decision-making concerning COVID-19 vaccination.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171674 | PMC |
| http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0285442 | PLOS |
Publication Analysis
Top Keywords
Similar Publications
The Association Between Obesity and COVID-19 Severity in Children Differed Between SARS-CoV-2 Variants: A Multicountry Hospital-Based Observational Study.
Pediatr Infect Dis J
September 2025
From the School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Queensland, Australia.
Background: Obesity was a risk factor for severe COVID-19 in children during early outbreaks of ancestral SARS-CoV-2 and the Delta variant. However, the relationship between obesity and COVID-19 severity during the Omicron wave remains unclear.
Methods: This multicenter, observational study included polymerase chain r eaction-confirmed SARS-CoV-2-infected children and adolescents from Australia, Brazil, Italy, Portugal, Switzerland, Thailand, the United Kingdom and the United States hospitalized between January 1, 2020, and March 31, 2022.
Measuring High-sensitive Cardiac Troponin Concentrations Predicted Hospital Deaths in Children With Severe Coronavirus Disease 2019.
Pediatr Infect Dis J
September 2025
From the Department of Pediatric Intensive Care Unit, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Background: Antiviral drugs and coronavirus disease 2019 (COVID-19) vaccines have significantly reduced COVID-19-related hospitalizations and deaths in infected children. However, COVID-19 continues to pose a major mortality risk in young children. High-sensitive cardiac troponin (Hs-cTn) is a specific marker of myocardial cell damage.
View Article and Find Full Text PDFA multi-omics recovery factor predicts long COVID in the IMPACC study.
J Clin Invest
September 2025
The University of Texas at Austin, Austin, United States of America.
Background: Following SARS-CoV-2 infection, ~10-35% of COVID-19 patients experience long COVID (LC), in which debilitating symptoms persist for at least three months. Elucidating biologic underpinnings of LC could identify therapeutic opportunities.
Methods: We utilized machine learning methods on biologic analytes provided over 12-months after hospital discharge from >500 COVID-19 patients in the IMPACC cohort to identify a multi-omics "recovery factor", trained on patient-reported physical function survey scores.
Diagnostic approach for post-COVID-19 mucormycosis.
Minerva Dent Oral Sci
September 2025
Department of Dental Research Cell, Dr. D.Y. Patil Dental College and Hospital, Dr. D.Y. Patil Vidyapeeth, Pune, India.
The COVID-19 pandemic, particularly in India, continues to pose a major threat to public health owing to the large number of patients that remain affected. The second wave of COVID-19 has brought with it several opportunistic diseases caused by bacteria and fungi, including mucormycosis, which is a well-known fungal infection primarily encountered in immunocompromised individuals through inhalation. In recent times, mucormycosis has become increasingly common in COVID-19 patients, particularly those with comorbidities such as diabetes, and has been observed to induce secondary infections as it spreads with COVID-19 treatment.
View Article and Find Full Text PDFGender and age differences in the risk of allergic reactions following the Pfizer-BioNTech COVID-19 and AstraZeneca vaccine using skin prick test and intradermal test among patients with high risk for hypersensitivity.
Allergol Immunopathol (Madr)
September 2025
Faculty of Medicine, University of Prishtina, University Clinical Center of Kosovo, Prishtina, Republic of Kosovo.
Objective: The aim of this study was to assess the association between allergic reactions after COVID-19 vaccination and the history of high-risk allergy, individual predisposing factors such as age and gender, and COVID-19 vaccine type.
Materials And Methods: This retrospective cohort study included 234 adult patients (18 years old and above) who underwent a COVID-19 vaccine allergy test up until February 2023 in a Clinic of Allergy and Clinical Immunology in the University Clinical Center of Kosovo. All patients suspected of allergy underwent skin testing: SPT (skin prick test) and IDT (intradermal test) using either an mRNA (ribonucleic messenger acid) vaccine (BNT162b2, Pfizer-BioNTech) and/or an adenoviral vector vaccine (AZD1222, AstraZeneca).